Gut · 2026
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maddalena Giulia, Aziz Kathryn, Sun Ryan, Newhook Timothy E, Alfaro Kristin, Bowling Andrew, Gil Dylan N, Behman Ramy S, Yousef Mahmoud, You Y Nancy, Konishi Tsuyoshi, Bent Alisha, Huey Ryan, Kee Bryan, Vetere Guglielmo, Osterlund Emerik, Ludford Kaysia, Serpas Victoria, Eluri Madhulika, Willis Jason, Shen John Paul, Morelli Maria P, Kopetz Emily, Lonardi Sara, Parseghian Christine, Raghav Kanwal, Overman Michael, Anandappa Gayathri, Wolff Robert A, Yao James, Chang George J, Morris Van K, Vauthey Jean-Necolas, Dasari Arvind, Kopetz Scott
Аннотация
BACKGROUND: The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients.
OBJECTIVE: The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints when adopting longitudinal MRD testing.
DESIGN: INTERCEPT, is a prospective, observational cohort study of stage II-IV patients with colorectal cancer receiving curative-intent treatment who are longitudinally monitored using tissue-informed MRD assays as part of routine clinical care.
RESULTS: Study results confirm the prognostic value of MRD, also beyond 12 months from surgery, with higher recurrence incidence in MRD-positive stage II-III patients than in MRD-negative stage IV patients (p<0.0001). Adjuvant therapy in stage IV disease showed limited durable benefit in both MRD-positive and negative patients. Clinical management was associated with increased use of more intensive second-line imaging (MRI, positron emission tomography; p<0.0001) when ctDNA was detected. Concurrent macroscopic disease detection was observed in 26% of cases and when excluded, LT from MRD detection to radiographic recurrence varies during surveillance (p=0.007). Multitimepoint testing improves sensitivity for recurrence (79.9% vs 48.5%) and may enable earlier, potentially curative interventions.
CONCLUSION: ctDNA testing provides a framework for risk stratification and defines temporal windows that may inform future interventional strategies. Prospective interventional studies are required to define clinical utility and optimal implementation.
OBJECTIVE: The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints when adopting longitudinal MRD testing.
DESIGN: INTERCEPT, is a prospective, observational cohort study of stage II-IV patients with colorectal cancer receiving curative-intent treatment who are longitudinally monitored using tissue-informed MRD assays as part of routine clinical care.
RESULTS: Study results confirm the prognostic value of MRD, also beyond 12 months from surgery, with higher recurrence incidence in MRD-positive stage II-III patients than in MRD-negative stage IV patients (p<0.0001). Adjuvant therapy in stage IV disease showed limited durable benefit in both MRD-positive and negative patients. Clinical management was associated with increased use of more intensive second-line imaging (MRI, positron emission tomography; p<0.0001) when ctDNA was detected. Concurrent macroscopic disease detection was observed in 26% of cases and when excluded, LT from MRD detection to radiographic recurrence varies during surveillance (p=0.007). Multitimepoint testing improves sensitivity for recurrence (79.9% vs 48.5%) and may enable earlier, potentially curative interventions.
CONCLUSION: ctDNA testing provides a framework for risk stratification and defines temporal windows that may inform future interventional strategies. Prospective interventional studies are required to define clinical utility and optimal implementation.